Capstan Medical has announced the successful closing of an oversubscribed US$110 million Series C, which will support it bringing its robotic structural heart solution to market. The round was led by Eclipse, with participation from existing investors Yu Galaxy and Intuitive Ventures, and new investment from Gideon Strategic Partners.
Capstan’s minimally invasive solution seeks to overcome limitations of current treatment options by bringing together novel heart valve implants and advanced catheter technology, fully enabled through a robotic platform, to treat a broader set of patients, the company says in a press release.
“Percutaneous intervention has the opportunity to dramatically increase the treatment options for the millions of people suffering from heart valve disease. At Capstan, we believe that our robotic platform with a full portfolio of implants can uniquely address the urgent needs of this underserved patient population,” said Maggie Nixon, CEO of Capstan Medical. “We have pulled together the right people at the right time to make this happen and are energised by the incredible support of our investors.”
“We’re at an inflection point where robotics will play a consequential role in delivering life-saving solutions to millions of patients across the world,” said Justin Butler, partner at Eclipse. “Capstan is at the forefront of this wave with their robotic solutions for structural heart disease.”
